Entertainment news, movies, and celebrities
As Boston's biotech sector grapples with talent migration to California, new discoveries in Alzheimer's research signal both change and opportunity.
As AI tools proliferate in healthcare, the erosion of physician autonomy raises questions about clinical judgment, responsibility, and professional independence.
Felix Wong's biotech startup thrives in California's culture despite his Massachusetts roots and impressive academic pedigree.
A recent Medicare policy change has postponed the price negotiations for a major AbbVie drug, potentially impacting taxpayers significantly.
A recent study reveals tau protein’s unexpected influence on cellular function, suggesting novel strategies for Alzheimer’s treatment.
The FDA has recently approved a new therapeutic drug and a vaccine, shaping the future direction of biotechnology and addressing pressing health needs.
Federal health officials convene with major tech firms to discuss the future of clinical AI, aiming for safe implementation and regulatory clarity.
A clinical trial indicates potential for fecal microbiome transplants to improve peanut allergy tolerance, exciting experts in the field.
A child’s death in a CRISPR gene-editing trial by HuidaGene raises serious concerns about safety and regulatory oversight in China’s biotech sector.
Moderna has launched a clinical trial for its mRNA-based Ebola vaccine, marking a significant step in combating this viral disease.
A recent Medicare pilot proposal risks reducing savings for retail drugs. Meanwhile, merger talks between AstraZeneca and Bristol Myers Squibb have been denied.
A new Medicaid toolkit emphasizes stricter oversight and measurable outcomes for autism therapies, raising concerns around ABA services and telehealth.
Excluding rare disease therapies from Medicare's drug pricing pilots could significantly reduce overall savings, according to recent research.
Despite high diagnosis rates, many U.S. men miss out on MRI screenings for prostate cancer, which could lead to better outcomes.
Novo Nordisk's ziltivekimab, aimed at targeting inflammation, showed no reduction in cardiovascular events despite lowering inflammation markers.
The American Diabetes Association, once praised for its bravery, now faces criticism for its handling of dissent within the medical community.
Recent critiques of a Covid study misrepresent key findings and overlook significant challenges in assessing nonpharmaceutical interventions' impacts.
In San Diego, a surge in syphilis cases highlights the challenges researchers face amid a drug shortage and complex patient interactions.
Capricor Therapeutics faces skepticism over its Duchenne MD therapy data, while the biotech sector grapples with leadership turmoil and FDA scrutiny.
Latigo Biotherapeutics' LTG-001 demonstrates significant pain relief in Phase 2 trials, marking a potential shift in non-opioid pain management options.